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Integrated heart/cancer on a chip to reproduce the
side eﬀects of anti-cancer drugs in vitro†
Ken-ichiro Kamei, *a Yoshiki Kato,b Yoshikazu Hirai,*ab Shinji Ito,c Junko Satoh,c
Atsuko Oka,c Toshiyuki Tsuchiya, b Yong Chenad and Osamu Tabatab
Pre-clinical animal tests are used to assess drug eﬃcacy and safety, but are limited by factors such as their
suitability as a model for humans, robustness, cost, and ethical issues. While an organ-on-a-chip using
human cells is promising for recapitulating human physiological conditions, it is highly desirable in
investigations of the side eﬀects of drugs to integrate more than one type of tissue using a designed
circulatory system. We have developed a microﬂuidic device—an Integrated Heart/Cancer on a Chip
(iHCC)—using human healthy heart cells (hCMs) and liver cancer cells (HepG2) to recapitulate the side
eﬀects of an anti-cancer drug, doxorubicin (DXR), to achieve individual cultures of cells from diﬀerent
tissues on a single device with three sets of artiﬁcial blood circulation loops, microfabrication technology
for micro valves and a pump provides accurate ﬂuid operation. Using improved soft lithography adopting
numerical optimization simulation, the microﬂuidic device was fabricated with on-chip integration of
pneumatic valves and a peristaltic micropump establishing precision ﬂuid ﬂow. The iHCC developed
allows modelling of the side eﬀects of DXR on heart cells caused by the production of toxic metabolites
(doxorubicinol; DXRol) by HepG2 cells and the delivery of DXRol to heart cells via the circulation loop.
Our ﬁndings open the door towards the development of a “Body-on-a-Chip.”
Introduction
Drug discovery is now facing issues such as high development
costs (over $10 billion US per drug) and long development times
(more than 10 years), as well as serious side eﬀects occurring
during clinical trials or aer introduction into the market.1
These problems are largely attributable to the current improper
approach to pre-clinical tests. For example, testing in animals,
such as rodents and non-human primates, might yield
misleading results because the response of these animals to
drug candidates is diﬀerent from that of humans. In addition,
the use of animals for drug discovery has become restricted in
many countries due to ethical issues.2 Therefore, pharmaceu-
tical companies take high risks in developing each new drug,
and new approaches for drug discovery are desired.
To address these issues, the “Organ on a Chip (OoC)”3–11 or
“Body on a Chip (BoC)”12–19 technologies, which can mimic
human physiological conditions in a microuidic device, hold
great promise as the next generation of pre-clinical tests.
Indeed, OoC and BoC were considered as being the “Top 10
Emerging Technologies of 2016” by the World Economic
Forum's Meta-Council on Emerging Technologies. In particular,
BoC technology allows the establishment of in vitro pre-clinical
drug tests capable of assessing absorption, distribution,
metabolism, and excretion processes (ADME) for pharmaceu-
tical compounds, all of which profoundly inuence the perfor-
mance and pharmacological activity of a compound. Because
BoC consists of multiple tissues in a single device, it also allows
observation of the interaction between diﬀerent tissues.
However, the current BoC platforms have several issues that
need to be solved prior to their realization. Most BoC platforms
have either a one-way ow stream or a few branches on a chip,
so they cannot completely mimic the blood circulation system,
or perform ADME tests for periods of days or weeks. Although
Maschmeyer et al. reported a four-organ-chip enabling co-
culture of human intestine, liver, skin, and kidney cells with
a medium circulation loop,20,21 it has not been using for drug
testing, and is still at the initial stage. Some studies have ach-
ieved medium circulation using an external rotary peristaltic
pump, but this requires a large amount of culture medium, and
drugs and metabolites might be lost to the tubing.22,23 To the
best of our knowledge, current devices have either a closed
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circulation loop to interconnect tissues or multiplexed capa-
bility within a single device. It is important to note that most of
the aforementioned OoC or BoC systems have only a single set
of experimental conditions in a chip, and do not allow side-by-
side comparisons within a device. Furthermore, the direct
integration of micropumps in the device oen causes diﬃcul-
ties in processing, such as incompatibility and reproducibility,
because the existing fabrication methods24–28 are not simple and
reliable. Therefore, it is important to develop new micro-
fabrication technologies capable of integrating pumps into
a device to minimize the volume of the tested medium and
prevent sample loss.
Here, we introduce a BoC, which we have named the Inte-
grated Heart/Cancer on a Chip (iHCC), which oﬀers (1) culture
of cells of diﬀerent tissues within a single device, (2) an articial
blood circulatory system in the form of a closed circulation loop
without the use of an external pump, and (3) three sets of loops
that can be used to apply diﬀerent conditions. By using this
iHCC, we provide proof of principle for recapitulation of the
side eﬀects and cardiotoxicity of an anti-cancer drug in vitro
(Fig. 1). The cardiotoxicity induced by anti-cancer drugs29 is
a major and serious concern in drug discovery, and the drug
metabolites generated from cancerous tissues might exert such
side eﬀects on normal tissues via the blood circulatory system
(Fig. 1A). In this study, doxorubicin (DXR)30 was selected
(Fig. 1B) as a model anti-cancer drug. DXR was originally ob-
tained from Streptomyces peucetius var. caesius, acts through
DNA intercalation, and has been used for treating a variety of
tumors, such as those of the lung, bladder, liver, breast, and
prostate.31 DXR exerts serious side eﬀects on the heart, such as
cardiomyopathy caused by undesired apoptosis.32 The use of
this combination of cells enables modelling of damage to the
heart caused by both the anti-cancer drug and its metabolite
produced in cancer cells. In this study, we attempted to repro-
duce the side eﬀects of DXR using human primary car-
diomyocytes (hCMs) from a healthy donor and human
hepatocellular carcinoma HepG2 cells, which have been widely




Design of the microuidic device used for iHCC. The iHCC
was constructed from polydimethylsiloxane (PDMS; SYLGARD
184, Dow Corning), consisting of a perfusion layer and a control
layer. PDMS was selected because it has good biocompatibility,
gas permeability, and light transparency (Fig. 2A).33,34 The
perfusion layer contained two cell culture chambers (2.1 mm in
width and 220 mm in height), suﬃcient to supply the required
growth factors, the anti-cancer drug, and allowing for reduced
shear stress.35 Microchannels were used to interconnect the two
cell culture chambers (150 mm in width, 45 mm in height)
through inlet and outlet holes. The control layer, consisting of
a thin and exible PDMSmembrane (200 200 mm2, and 20 mm
thickness), contained pneumatic valves24 to allow for the inde-
pendent culture of two types of cells without cross contamina-
tion, and peristaltic micro pumps36 for precision medium ow
control. Membrane actuation at the valves and pumps was
performed by varying the positive hydraulic pressure from the
control channel located under the perfusion layer, which was
achieved using computer-controlled solenoid valves for accu-
rate control. The micro pump consisted of three individual
valves, providing a peristaltic motion for programmable uid
actuation. This micro pump was utilized for an embedded
closed-circulation loop35 as an articial circulation system to
interconnect diﬀerent cells (Fig. 2B). The set of micropumps
and embedded circulation loop minimizes the loss of medium
volume and reduces sample loss. Thus, this device comprised
three sets of two cell culture chambers with a closed-circulation
loop to allow for three diﬀerent but simultaneous cell treat-
ments within a device (Fig. 2C).
Device fabrication. A multilayer so lithography replica
molding technique was used for device fabrication (Fig. 3).24,37
The control layer was cast against the negative photoresist mold
with microuidic channel features with a thickness of 30 mm
(TMMR S2000, Tokyo Ohka Kogyo) patterned by standard UV
lithography. A resist mold for the perfusion layer was fabricated
by a combination of standard UV lithography and grayscale
lithography. First, the negative resist layer (TMMF S2045, Tokyo
Ohka Kogyo) (thickness, 220 mm) was patterned for the perfu-
sion layer using standard UV lithography. Next, the positive
resist layer (PMER P-LA900PM, Tokyo Ohka Kogyo) was spin-
coated at a thickness of 45 mm to fabricate the resist mold for
the microchannels and pneumatic portions, and then digital
micromirror device (DMD)-based lithography (DL-1000GS/KCH,
NanoSystems Solutions) was performed.38
Fig. 1 Communication between liver cancer cells and healthy heart
cells via exchange of metabolites, and the side eﬀects of an anti-
cancer drug. (A) Illustration of the anti-cancer eﬀect of doxorubicin
(DXR) according to the metabolic activity of liver cancer and the side
eﬀects of a DRX metabolites on the healthy heart. Although the anti-
cancer drug could eﬀectively cure liver cancer, its metabolite might
travel to healthy tissues, such as the heart, and cause damage to those
tissues. (B) Our proposed in vitromodel to recapitulate the side eﬀects
of DXR using two types of cells: a liver cancer cell line (HepG2) and
primary human cardiomyocytes (hCM). In the co-culture system,
a drug metabolite might be released from HepG2 cells by metabolic
activity, and reach hCM cells, thereby causing cell damage.





















































































For the pneumatic portion, DMD-based grayscale lithog-
raphy using numerical optimization38,39 was employed for
wafer-level fabrication (Fig. 3).
Aer fabrication of the resist molds, the PDMS base and
curing agents (1 : 10 with a weight ratio, curing agent : base)
were mixed well, degassed in a vacuum desiccator, and poured
on the mold structures for the perfusion layer. Aer curing in
a convection oven at 80 C, the perfusion layer was released
from the resist mold. Similarly, for the PDMS layer (thickness,
20 mm), the PDMS membrane was fabricated with the control
layer by spin-coating the PDMS pre-polymer onto a resist mold.
Aer spin-coating, the control layer was cured at 80 C. The two
cured PDMS layers were aligned under a microscope and
bonded onto the control layer using the partial PDMS curing
method,40,41 allowing for the spontaneous adhesive interaction
between the two PDMS layers. Finally, the assembled device was
permanently bonded using O2 plasma surface treatment (FA-1,
SAMCO) onto a microscopic glass slide (25 mm  75 mm).
Device control. The pneumatic control setup consisted of
two sets of eight-channel manifolds (Microuidic SystemWorks
Inc. and THE LEE Company). The setup was controlled using
a controller board (VC3 8 controller [ALA Scientic Instruments]
and NI USB-6501 [National Instruments]), connected to
a computer through a USB port. Compressed nitrogen gas
provided pressure (200 kPa) to the manifolds. Metal pins con-
taining Tygon Microbore tubing (Saint-Gobain) lled with water
were inserted to the holes of the top perfusion layer connected
to the valves and pump, as indicated by the dark blue color
shown in Fig. 2C. The other end of the Tygon Microbore tubing
was connected to the corresponding control channels on the
manifolds. Control channels in the chips were rst lled with
DI-water by applying pressure (30 kPa). The electronic manifold
interface was created using LabVIEW (Version 11.0, National
Instrument Inc.).
Cell culture. HepG2 hepatocellular carcinoma cells were
obtained from American Type Culture Collection. HepG2 cells
were maintained in Dulbecco's modied Eagle medium
(DMEM; Thermo Fisher Scientic) supplemented with 10% (v/v)
fetal bovine serum (FBS, Cell Culture Bioscience), 1% (v/v) non-
essential amino acids (Thermo Fisher Scientic), and 1% (v/v)
penicillin/streptomycin (Thermo Fisher Scientic), referred to
as HepG2 medium. Culture medium was changed every two
days, and the cells were passaged with TrypLE express every four
days.
Human primary cardiomyocytes (hCMs) were obtained from
PromoCell, and were maintained in myocyte medium (Promo-
Cell) supplemented with 0.05% (v/v) fetal calf serum (Promo-
Cell), 0.5 ng mL1 recombinant human epidermal growth factor
(PromoCell), 2 ng mL1 recombinant human basic broblast
growth factor (PromoCell), and 5 mg mL1 recombinant human
insulin (PromoCell) in a humidied incubator at 37 C and 5%
(v/v) CO2. Cell culture medium was changed every three days,
and the cells were passaged using a trypsin/
ethylenediaminetetraacetic acid (EDTA) (0.04%/0.03% [v/v])
solution (Thermo Fisher Scientic) every week.
Cell culture in iHCC. Prior to the use of iHCC for cell culture,
the chip was washed with 70% (v/v) ethanol and irradiated with
UV light to prevent contamination. Next, 100 mg mL1 human
recombinant bronectin (Thermo Fisher Scientic), 0.1% (w/v)
bovine gelatin (Type B, Sigma-Aldrich), or 1.3% (v/v) Matrigel
hESC (human embryonic stem cell)-Qualied Matrix (Corning)
in DMEM/F12 medium (Thermo Fisher Scientic) was intro-
duced into the chip using a syringe inserted at the inlet hole,
and incubated at 4 C for at least 16 hours to allow for coating of
the extracellular matrices. Aer rinsing excess Matrigel with
DMEM/F12 medium, the chip was placed in an incubator at
37 C until use.
HepG2 and hCM cells were harvested from culture asks
using 2 mL of trypsin/EDTA (0.04%/0.03% [v/v]) solution and
incubated at 37 C for 5 minutes. Aer addition of 1 mL of
trypsin neutralizing solution (TNS; PromoCell) to the hCM
sample, HepG2 and hCM cells were resuspended in their cor-
responding medium at 1.0  106 cells per mL. Following this,
Fig. 2 Design of the microﬂuidic device used for iHCC. (A) Illustration
of the side view of iHCC. The device consists of a “perfusion layer” and
“control layer”, and was constructed from polydimethylsiloxane
(PDMS) as shown in grey. (B) A set of cell culture chambers with
a medium circulation systemmimics the blood circulatory system that
interconnects various tissue cells. Integrated valves (red) allow precise
control of the ﬂuids as well as introduction of cell/reagents. A pneu-
matic pump (yellow) provides medium circulation within a set of two
cell culture chambers (“i” and “ii” for HepG2 and hCM, respectively). (C)
Photograph of an actual iHCC fabricated on a glass slide (25 mm  75
mm). This device has three sets of co-culture systems, and the dashed
line indicates one of them as shown in (B). The operation of pneumatic
valves and peristaltic pumps is controlled by custom LabVIEW-based
software. The pink color indicates the top layer containing the cell
culture chambers, and the dark blue color indicates the bottom layer
containing the valves and pumps.





















































































10 mL of the cell suspension was introduced using a pipette into
the hole adjacent to the cell culture chamber to plate the device
with cells at 7.0  104 cells per cm. The cell-loaded device was
then placed in a humidied incubator at 37 C under 5% (v/v)
CO2.
Cell treatment in iHCC. Prior to cell treatment with doxo-
rubicin (DXR; Sigma), DXR was dissolved in dimethylsulfoxide
(DMSO; Wako), to give a 10 mM DXR stock solution. Cells were
treated with 20 mMDXR in 0.1% (v/v) DMSO in hCMmedium for
24 hours with or without medium circulation. As positive and
negative controls (PC and NC, respectively) for cell damage,
hCM medium supplemented with 1 mM staurosporine (STS;
Wako) in 0.1% (v/v) DMSO, or 0.1% (v/v) DMSO, were used
respectively. Medium circulation was applied using an inte-
grated pump at 0.25 Hz and 200 kPa, controlled by the LabVIEW
program (National Instruments). Every six hours, fresh hCM
medium, present in the tubing inserted at the inlet port, was
introduced automatically. During cell treatment, the iHCC was
placed in a humidied incubator at 37 C under 5% (v/v) CO2.
Cell treatment in a 96-well plate. Following the same
procedure that was used in “Cell culture in iHCC,” HepG2 and
hCM cells were harvested from a cell culture ask. Subse-
quently, 100 mL of 1  105 cells per mL cell suspension in their
corresponding medium was introduced in each well of a 96-well
plate to give a cell density of 7.0  104 cells per cm, and then
cultured in a humidied incubator at 37 C under 5% (v/v) CO2
for 24 hours. For cell treatment, 20 mM DXR in hCM medium
containing 0.1% (v/v) DMSO was used. As PC and NC for cell
damage, hCMmedium supplemented with 1 mM STS in 0.1% (v/
v) DMSO or with only 0.1% (v/v) DMSO, respectively, was used.
Staining of proliferating cells. Staining of proliferating cells
with EdU was performed according to the product manuals of
the Click-iT EdU Imaging Kit (Thermo Fisher Scientic). Briey,
aer cell treatments, cells were treated with hCM medium
supplemented with 10 mM EdU in a humidied incubator at
37 C under 5% (v/v) CO2 for 30 min. Aer washing away excess
EdU with hCM medium, the cells were xed with 4% para-
formaldehyde for 15 min at 25 C, followed by permeabilization
(0.3% Triton X-100 in PBS) for 16 hours at 25 C. EdU incor-
porated into cellular DNA was labeled with Alexa Fluor 647 by
means of a click reaction.
Dead cell staining. Aer cell treatment, cells were treated
with 300 nM 40,6-diamidino-2-phenylindole (DAPI, Thermo
Fisher Scientic) dissolved in hCM medium (without DXR, STS,
or DMSO), and incubated in a humidied incubator at 37 C
under 5% (v/v) CO2 for 30 min. Next, excess uorescent dye was
rinsed oﬀ and replaced with DMEM/F12 medium without
phenol red for cell microscopic imaging.
Fig. 3 Fabrication of the integrated Heart/Cancer on a Chip (iHCC) microﬂuidic device. The device was fabricated as follows: (1) for the control
layer, the negative resist was patterned on a Si wafer and was used as a casting mold. A casting mold of the perfusion layer was fabricated by
a combination of the negative resist patterning and grayscale lithography using positive resist coating. Following this, digital micromirror device
(DMD)-based grayscale lithography (DL-1000GS/KCH, NanoSystems Solutions) combined with the simulation-based fabrication approach was
employed as described in the previous reports.38,39 (2) The PDMS pre-polymer was poured onto the mold structure and cured. (3) The perfusion
layer was bonded onto the control layer. (4) The assembled structure containing the perfusion and control layers was bonded onto a glass
substrate using oxygen plasma treatment.





















































































Image acquisition and processing. The device was placed on
the stage of a Nikon ECLIPSE Ti inverted uorescence micro-
scope equipped with a CFI Plan Fluor 4/0.13 N.A. objective
lens (Nikon), CCD camera (ORCA-R2, Hamamatsu Photonics),
mercury lamp (Intensilight, Nikon), XYZ automated stage (Ti-S-
ER motorized stage with encoders, Nikon), and lter cubes for
two uorescence channels (DAPI and Cy5; Nikon). The images
were acquired using all motorized components (stage, lters,
shutter, and focus system) that were controlled by the manu-
facturer's NIS-elements imaging soware. The exposure times
were set at 1 s for DAPI (DAPI channel) and EdU (Cy5 channel).
Following image acquisition, the CellProler soware (Broad
Institute of Harvard and MIT, Version 2.1.0)42 was used for
identifying cells by employing Otsu's method, and the uores-
cent signals in individual cells were quantied automatically.
Ultra-high-performance liquid chromatography-tandem
mass spectrometry. Culture medium (24 mL) was mixed with 1
mL of internal standard (IS) solution. IS solution was prepared
by mixing daunorubicin (DNM) hydrochloride (Sigma) with
fresh culture medium at 3 mM. The solution was mixed with 75
mL of acetonitrile, vigorously mixed for 30 s, and centrifuged
(16 000  g, 10 min, 4 C), and 30 mL of the supernatant was
mixed with 82.5 mL of 5.45 mM ammonium acetate (pH 3.5).
Part of the resulting solution (30 mL) was separated on a Nexera
UHPLC system (Shimadzu) using a binary gradient. The
gradient program was as follows: 20 to 30% (v/v) B in 8 min, 40
to 100% (v/v) B in 2 min, 100% (v/v) B for 2 min, 100 to 20% (v/v)
B in 0.01 min, then 20% (v/v) B for 3 min. The ow rate was set
to 0.4 mLmin1. Mobile phases A and B were 5 mM ammonium
acetate (pH 3.5) and acetonitrile, respectively. An ACQUITY
UPLC CSH C18 column (130 A˚, 1.7 mm, 2.1 mm  100 mm
(Waters)) was used at 40 C. The UHPLC eluates were infused
online to the LC-MS 8030 plus system (Shimadzu), which was
set to positive electrospray ionization (ESI) mode. The responses
for DXRol, DXR, and DNM were monitored by multiple reaction
monitoring (MRM) with transitions m/z 546.10 > 399.20, 544.10
> 397.20, and 528.15 > 321.15, respectively. All measurements
were obtained in triplicate and the averaged responses were
used. MRM transitions were optimized and peak areas were
calculated using Labsolutions soware (Shimadzu). The
responses for DXRol and DXR were normalized to that of DNM
in each sample. The calibration plots were prepared by
measuring standard samples, which were generated by adding
increasing amounts of DXR and DXRol and xed amounts of
DNM to fresh medium. Because HepG2 cells and hCMs were
cultured with diﬀerent media, the calibration plots were inde-
pendently prepared for each medium to compensate for matrix
eﬀects.
Lactate dehydrogenase (LDH) cytotoxicity assay. The LDH
cytotoxicity assay (Cytotoxicity Detection Kit PLUS, Roche) was
performed by following the manufacturer's instruction. Briey,
aer cell stimulation, the cell culture supernatant was har-
vested, and 100 mL of the supernatant was transferred into a well
of a fresh 96-well plate. Then, 100 mL of a reactionmixture in the
kit was added to the well and incubated at room temperature for
10 min. The reaction was stopped by adding the stop solution in
the kit. Finally, the absorbance of the samples was measured at
490 and 690 nm.
Statistics. Statistical analyses, such as MannWhitney's U test




To characterize the performance of the directly embedded
valves and the micropump, the threshold hydraulic pressure to
completely close the microchannels was calibrated before the
cell culture experiments. During the calibration, the control
channels in the control layer were lled with DI water and
pressurized using nitrogen gas with a pressure regulator. The
inlet and outlet of the perfusion layer were connected to tubes
Fig. 4 Characterization of the embedded micro valves and pump. (A)
A valve eﬃciency (DQ/Q) comparison between grayscale lithography
and standard lithography. DQ andQ are the ﬂow rate change and ﬂow
rate when the valve is opened, respectively. In the case of standard
lithography, a square shaped microchannel was used, which has the
same width and height as that fabricated using grayscale lithography.
(B) Fluorescent images of the integrated pneumatic valve in the open
and closed states at the applied hydraulic pressure of 65 kPa. (C)
Volumetric ﬂow rate generated by the micro pump. The ﬂow was
measured by observing the moving water front without gravity ﬂow.
The measured volumetric ﬂow rate was observed after applying
a hydraulic pressure of 65 kPa. A ﬂow rate of 26 nLmin1 was obtained
under a driving pressure of 100 kPa at 2 Hz at the micropump.





















































































and the gravity ow of DI water was generated at a pressure
head of 400 mm. The ow rate was measured by means of the
progress of the water front in the tube, and the valve eﬃciency
was then dened by a change in relative ow rate. The eﬃciency
of the valve fabricated by grayscale lithography increased
steeply until it reached hydraulic pressure of 63 kPa compared
to that of standard lithography (Fig. 4A). Taken together with
the numerical simulation of a 200  200 mm square PDMS
membrane having a threshold hydraulic pressure of 65 kPa
(CoventorWare, Coventor), the measurements agree with the
threshold hydraulic pressure obtained from the simulation
(diﬀering by less than 3%).39 The uorescent images of the
integrated pneumatic valve in the open and closed states,
revealed that the valve was 100% closed at a hydraulic pressure
of 65 kPa (Fig. 4B). On the other hand, the eﬃciency of the valve
fabricated by standard lithography continuously increased and
did not close completely due to restrictions in PDMS's
mechanical deformability at the microchannel edges. The
volumetric ow rate generated by the micropump was also
measured by observing the moving water front without gravity
ow (Fig. 4C). The measured volumetric ow rate was observed
aer the applied hydraulic pressure reached 65 kPa; under
a driving pressure of 100 kPa, a ow rate of 26 nL min1 was
obtained at 2 Hz. At this ow rate, drugs andmetabolites moved
from one chamber to another in two minutes. These data show
that the present microfabrication technology can achieve reli-
ability and accurate valve and micro pump actuation.
Cell culture in iHCC
To accomplish our iHCC goal, we rst conrmed the applica-
bility of our device for co-culturing two diﬀerent cell types with
circulation of the medium and then established an in vitro cell-
based assay for reproduction of the side eﬀects of DXR in the
device.
To determine whether the fabricated device allowed simul-
taneous culture of two diﬀerent cells, we introduced hCMs and
HepG2 cells into the device and cultured them (Fig. 5A). Prior to
cell culture, the culture chambers were coated with extracellular
matrix (ECM) components such as bronectin, gelatin, or
Fig. 5 Cell culture in the iHCC. (A) Procedure for cell culture and drug testing in the iHCC. The red and black squares represent the open and
closed valves, respectively. The set of three yellow squares represents a peristaltic pump comprised of three pneumatic valves. (1) To facilitate cell
adhesion and growth, Matrigel was ﬁrst introduced using a syringe inserted at the inlet hole, and coated in the cell culture chamber at 4 C for at
least 16 hours after which the excess Matrigel was removed. (2) Following this, both cancer and heart cells were introduced into separate
chambers using a pipette and a hole adjacent to the cell culture chamber, and incubated in a humidiﬁed incubator at 37 C for 24 hours. (3) After
cell culture, medium circulation was started, with and without the drug solution, using the embedded micropumps for 24 hours. (4) Finally, DAPI
was introduced and cells were incubated in a humidiﬁed incubator at 37 C for 30 min to observe cell damage. See also ESI† (B, C) micro-
photograph of human primary cardiomyocytes (hCMs; B) and HepG2 cells (C) cultured in iHCC under medium circulation after 24 hours. Scale
bar, 100 mm.





















































































Matrigel at 4 C for at least 16 hours. Matrigel was found to be
a more eﬀective ECM than bronectin and gelatin for both cell
types, in terms of cell proliferation for the rst 24 hours (data
not shown). When changing the medium, 10 mL of fresh culture
medium for each cell type was placed in a tube and introduced
from an inlet into the respective cell culture chamber using
a pipette. During cell culture, iHCC was placed in a humidied
incubator at 37 C under 5% (v/v) CO2. Aer introducing the
cells, it took approximately three hours for the cells to attach to
the Matrigel-coated substrate. Because PDMS is a porous
material, CO2 was able to penetrate through the PDMS of iHCC
and reach the cell culture chambers. Therefore, the pH in iHCC
wasmaintained due to the equilibrium of HCO3
 and CO2. Both
cell types reached over 80% conuence aer one day of culture
on the chip without any damage. Aer establishing cell culture
in each chamber, we also set up a closed-loop medium circu-
lation. For this, we used hCM medium, which was changed
every 6 hours. Although hCM medium was not established for
HepG2 cells, both HepG2 and hCM cells showed normal
morphology as well as growth in the circulating medium
(Fig. 5B and C). These results suggest that the hCM medium
allowed culture of both hCMs and HepG2 cells without damage
during cell culture and treatment.
Drug testing in iHCC
Next, we performed iHCC-based assays to evaluate the eﬃcacy
and toxicity of DXR (Fig. 6). As a comparison, a conventional
cell-based assay was also performed in a 96-well plate, in which
only static conditions could be applied to the cells, and the
interaction between hCMs and HepG2 cells via metabolites
released from cells in cell culture medium could not be
observed. As a positive control (P.C.) for cell damage,
Fig. 6 Doxorubicin (DXR) has anti-cancer eﬀects against HepG2
hepatocellular carcinoma cells by reducing the number of proliferating
cells in both the iHCC and in a 96-well plate. (A) Fluorescent micro-
graphs of ﬁxed HepG2 cells stained with 300 nM DAPI and 10 mM EdU
in the iHCC. HepG2 cells were cultured in hCM medium in the iHCC
for 24 hours. EdU stains only proliferating cells. DAPI was used to stain
all nuclei in the ﬁxed cells. Scale bar, 200 mm. (B) Quantitative single-
cell proﬁling to reveal the eﬀects of 20 mMDXR in hCMmedium for 24
hours on living HepG2 cells cultured using the iHCC (left) and a 96-
well plate (right). Fluorescent EdU intensity in over 3000 cells was
analysed for each sample. Cell treatment with 1 mM staurosporine (STS)
for 24 hours was used as a positive control for cell damage. hCMs
treated with only 0.1% DMSO in hCM medium for 24 hours were used
as a negative control (N.C.). DAPI staining was performed to visualize
damaged cells. P-Values (*** < 0.001) were determined by Mann
Whitney's U test. The center lines show the medians; box limits indi-
cate 25% and 75%; whiskers extend 1.5 times the interquartile range
from 25% and 75%.
Fig. 7 iHCC serves as an experimental platform to model the side
eﬀects of the anti-cancer drug doxorubicin (DXR). (A) Fluorescent
micrographs of hCMs treated with 20 mM DXR in hCM medium for 24
hours in the iHCC. Staurosporine (STS; 1 mM) in hCM medium for 24
hours was used as a positive control for cell damage. DAPI staining was
performed to visualize damaged cells. Untreated hCMs were used as
the negative control (N.C.). Scale bar, 200 mm. (B, C) Quantitative
single-cell proﬁling to reveal the eﬀects of DXR on damaged HepG2
cells and hCMs cultured in a 96-well plate under static conditions (B)
and in iHCC with closed medium circulation (C). DAPI ﬂuorescence
intensity in over 3000 individual cells was analyzed for each sample. P-
Values (*** < 0.001) were determined using Mann Whitney's U test.
The center lines show the medians; box limits indicate 25% and 75%;
whiskers extend 1.5 times the interquartile range from 25% and 75%.





















































































staurosporine (STS)43 was used to induce apoptosis. As a nega-
tive control (N.C.), a mock solution (hCM medium supple-
mented with 0.1% (v/v) DMSO) was used. EdU was used as an
indicator of cells in the S-phase, as DXR inhibits cell prolifera-
tion by intercalating into the genome during DNA duplication.
In both experimental setups, HepG2 cells treated with 20 mM
DXR reduced EdU accumulation to levels comparable to those
in cells treated with STS, resulting in lower cell proliferation
(Fig. 6B). This result indicated that DXR showed anti-cancer
eﬀects on HepG2 cells. We also attempted EdU staining of
hCMs, but since these were non-cancerous healthy cells and do
not proliferate, no EdU signal was obtained, in contrast to
HepG2 cells (Fig. S1 in ESI†).
For better observation of DXR-induced cell damage, DAPI
uorescent dye was used as a dead cell assay (Fig. 7A).44,45 DAPI
does not pass through the intact cell membrane, but penetrates
the membrane of damaged or apoptotic cells and binds to the
DNA. Therefore, DAPI uorescence is only observed for dead or
apoptotic cells. To conduct a cell-based assay in a microuidic
device, in situ methods such as cell imaging9 and the use of
integrated sensors22 are more suitable than other methods
involving cell lysis (e.g., enzyme-linked immune-sorbent assay,
western blotting or quantitative polymerase chain reaction) or
secretion (e.g., secreted alkaline phosphatase assay) because of
the lack of sample loss in the device and tubing. To quantita-
tively analyze cell damage, single-cell proling was also con-
ducted using both iHCC and a parallel 96-well plate. Under
static conditions in the 96-well plate, the number of cells
damaged by DXR increased slightly, but only for HepG2 cells
(***p < 0.001, compared with N.C.), and not for the hCMs
(Fig. 7B). This result indicated that DXR exerted an appropriate
anti-cancer eﬀect on HepG2 but did not cause cell damage to
the hCMs. In contrast, the iHCC experiment produced diﬀerent
results (Fig. 7C). Following the application of closed-loop
medium circulation with DXR in iHCC, the number of
damaged hCMs increased signicantly (***p < 0.001, compared
with NC), whereas no cell damage was observed without DXR. In
light of these results, we hypothesized that the cytotoxicity was
attributable to DXR metabolites being released from HepG2
cells, rather than to DXR itself, which then reached the hCM
cells via the circulating medium.
DXRol (doxorubicinol), a known DXR metabolite, was used
to validate our hypothesis.46,47 While the side eﬀects of DXR on
cardiomyocytes and its toxicity mechanism has been intensively
studied, the eﬀects of DXRol are not known. First, we measured
the levels of DXRol produced from DXR-treated HepG2 and
hCM cells (Fig. 8A le panel and Fig. S2†). HepG2 cells
produced 0.20 mM of DXRol in 100 mL cell culture medium by
metabolizing DXR, but hCMs did not. In fact, the amount of
DXR in HepG2 culture was reduced compared with that in hCM
culture due to its metabolism to DXRol (Fig. 8A right panel). To
investigate the cytotoxic eﬀects of DXR and DXRol, release of
lactate dehydorogenase (LDH), a well-known indicator of cell
damage, was determined in the 96-well plate assay (Fig. S3†).
While 20 mM DXR was cytotoxic to HepG2 cells, lower DXR
concentrations did not show cytotoxicity. In terms of hCMs,
DXR did not induce LDH release, indicating that DXR did not
cause cell damage. In contrast, 20 mM DXRol caused cytotoxic
eﬀects in hCMs, but not in HepG2 cells. As shown in Fig. 8A,
HepG2 cells produced only 0.20 mM DXRol from DXR, but this
concentration did not cause cell damage to hCMs. This diﬀer-
ence is largely due to the diﬀerences between the iHCC and 96-
well plate systems. In the case of the 96-well plate, metabolites
released from cells might be diluted in the cell culture medium,
whereas, in the case of iHCC, the metabolites were not diluted
as much due to the smaller volume used for cell culture.
Therefore, metabolites released from cells in the iHCC might
more eﬀectively aﬀect other cells than they would aﬀect the cells
in a 96-well plate. In this regard, further analysis using a 96-well
plate assay and 20 mM of DXR and DXRol were used. To test the
Fig. 8 Doxorubicinol (DXRol), but not doxorubicin (DXR), showed toxic eﬀects on human cardiomyocytes (hCMs). (A) HepG2 cells metabolized
DXR to DXRol, but hCMs did not (left panel). The DXR amount in the HepG2 culture was reduced compared with that in the hCM culture (right
panel). HepG2 cells and hCMs were cultured in a 96-well plate and treated with DXR (20 mM) for 24 hours. The culture medium supernatant was
collected and analysed using ultra-high-performance liquid chromatography-mass spectrometry to measure both DXR and DXRol. (B) Quan-
titative single-cell proﬁling to investigate the eﬀects of doxorubicin (DXR) and its metabolite, doxorubicinol (DXRol), on hCMs. hCMs were
cultured in a 96-well plate and treated with DXR (20 mM) or DXRol (20 mM) for 24 hours. DAPI ﬂuorescence intensity in over 200 individual cells
was analyzed for each sample. P-Values (*** < 0.001) were determined by Steel-Dwass test. The center lines show the medians; box limits
indicate 25% and 75%; whiskers extend 1.5 times the interquartile range from 25% and 75%.





















































































eﬀects of DXRol on the proliferation of HepG2 cells, an EdU cell
proliferation assay was carried out (Fig. S4†). As a result, DXRol
signicantly reduced the EdU staining intensity (***P < 0.001),
indicating reduced cell proliferation; this result was similar to
that obtained for DXR. Furthermore, hCMs treated with DXRol
had more cell damage than hCMs treated with DXR or the N.C.
(***P < 0.001; Fig. 8B). These results suggest that DXR is not
toxic to healthy cardiomyocytes, but its metabolite DXRol is very
toxic to cardiomyocytes.
Conclusions
In conclusion, we propose a proof of concept for recapitulation
of the cardiotoxic side eﬀects of an anti-cancer drug in vitro
using a simple iHCC, which comprises a microuidic device
allowing for integrated culture of cancer and heart cells. The
iHCC developed here permits (1) culture of cells from diﬀerent
types of tissues within a single device, (2) application of a closed
circulation loop as an articial blood circulatory system, and (3)
multiple sets of diﬀerent samples to be used for systematic
tests. Essentially, it allows a drug to travel through tissues via
the circulation loop and to produce tissue-specic metabolites.
Thus, the cytotoxicity of an anti-cancer drug on cancer cells and
normal cardiomyocytes can be successfully evaluated within
a device, thereby recapitulating the side eﬀects. Because this
cannot be achieved using conventional cell cultureware, iHCC
oﬀers great advantages over conventional OoC/BoC platforms to
accurately reproduce human physiological conditions by eﬀec-
tively utilizing its circulation loop to connect diﬀerent tissues.
Furthermore, the proposed fabrication method for on-chip
integration of micro pumps is scalable and applicable for
other studies. Therefore, this is the rst step in recapitulating
the side eﬀects of a drug using the OoC/BoC platforms.
To make more advanced BoC platforms, there are several
requirements. First, the use of more functional tissues for
accurate drug testing is needed and this means that three-
dimensional cell culture needs to be performed in these BoC
platforms. Of course, the microuidic technique oﬀers chem-
ical and physical control over three-dimensional cellular envi-
ronments.33,34,48–50 These advantages should allow for the
generation of environments highly suitable for cells to express
their functions, even in vitro.
Second, PDMS is known to absorb small molecules, such as
hydrophobic molecules,19 which might inuence the pharma-
cological results.51 Although alternatives to PDMS have been
under development for a long time,39 no suitable substitutes are
yet available. Therefore, a new material enabling better phar-
macological studies needs to be developed.
Third, it is also important to note that the cell culture
medium needs to be optimized for the tested cell types, espe-
cially, for performing BoC experiments for longer periods, such
as a month or more. In this study, we used the hCMmedium for
both cardiomyocytes and hepatocellular carcinoma cells. This
issue can be addressed by both development of the cell culture
medium and design of the microuidic device.
Fourth, it is also important to note that the results obtained
using the BoC platform need to be reconciled with
pharmacological data obtained in either preclinical animal
studies or clinical trials. Therefore, it is also necessary to design
experiments and analyses to compare iHCC-based and
preclinical/clinical trial data.
Finally, we envision that by applying the recently developed
induced pluripotent stem cell technology and increasing the
number and complexity of tissues using advanced micro-
engineering technology, this platform will be able to recapitu-
late physiological and pathological conditions for precise
investigation of drug eﬃcacy and toxicity, which would be
a signicant step toward realizing personalized medicine.
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